Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients
| Autor: | Arjen Nikkels, Murielle Sabatiello, Sofie De Schepper, Eve Lebas, Virginie De Schaetzen, Florence Libon |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Immunology Severity of Illness Index Etanercept Acitretin chemistry.chemical_compound Psoriasis Ustekinumab medicine Adalimumab Humans Immunology and Allergy Child Calcipotriol business.industry Antibodies Monoclonal medicine.disease Dermatology Ixekizumab Treatment Outcome chemistry Secukinumab business medicine.drug |
| Zdroj: | Expert Review of Clinical Immunology. 17:947-955 |
| ISSN: | 1744-8409 1744-666X |
| Popis: | Introduction Psoriasis affects around 2% of children in Europe. The majority of cases is readily managed with topical treatments using corticosteroids without or with calcipotriol. More resistant and extensive moderate-to-severe cases require UVA or UVB phototherapies or conventional systemic treatment including ciclosporin, acitretin and methotrexate. However, these therapies are associated with a low tolerability and potential cumulative long-term adverse effects and toxicities. Areas covered About 15 years ago, the first biological appeared for the treatment of moderate-to-severe plaque type psoriasis in adult patients. Several years later, the first biologic treatment to be approved in children was etanercept, a soluble receptor that binds both tumor necrosis factor (TNF)-α and β followed by adalimumab, a monoclonal antibody against TNF-α, and currently by ustekinumab, a monoclonal IL12/23 p40 antagonist and, very recently, secukinumab and ixekizumab, both IL17 antagonists. All these biologic treatments brought significantly improved treatment results compared to light-based therapies and conventional treatments and present very good tolerance and safety profiles. Expert opinion Due to their excellent efficacy and safety profiles ustekinumab, secukinumab and ixekizumab could currently be considered as a first-line treatment options for moderate-to-severe childhood and adolescent psoriasis requiring a systemic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|